SCHEMBL10318005

SCHEMBL10318005

COCCOc1cc2cc(C(=O)Nc3cc(C(=O)O)ccc3C)c(=O)[nH]c2cc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.73
▸ DYRK1B Q9Y463 3/20 0.73
▸ MAPT P10636 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.43
▸ GAA P10253 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ PPARG P37231 2/20 0.41
▸ ABCG2 Q9UNQ0 2/20 0.41
▸ CNR2 P34972 1/20 0.41
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10317577 0.93 DYRK1A (0.85) DYRK1ADYRK1BMAPTALDH1A1ABCG2
SCHEMBL10318061 0.93 DYRK1A (0.85) DYRK1ADYRK1BMAPTALDH1A1ABCG2
SCHEMBL10319139 0.92 DYRK1A (0.84) DYRK1ADYRK1BMAPTALDH1A1GAA
SCHEMBL10319359 0.90 DYRK1A (0.58) DYRK1ADYRK1B
SCHEMBL10321365 0.90 DYRK1A (0.80) DYRK1ADYRK1BMAPTALDH1A1GAA
SCHEMBL10319373 0.86 DYRK1A (0.61) DYRK1ADYRK1BMAPTALDH1A1KDM4E
SCHEMBL10379514 0.85 DYRK1A (0.90) DYRK1ADYRK1B
SCHEMBL10318281 0.85 DYRK1A (1.00) DYRK1ADYRK1BMAPTALDH1A1HDAC8
SCHEMBL10379493 0.84 DYRK1A (0.80) DYRK1ADYRK1B
SCHEMBL10379231 0.84 DYRK1A (0.80) DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098070-A1 QUINOLINE DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
WO-2012098070-A1 QUINOLINE DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184548-A1 CARBOXYLIC ACID ARYL AMIDES DOMINIQUE ROMYR (US) 2012-07-19 — — US disclosed
US-20120184548-A1 CARBOXYLIC ACID ARYL AMIDES DOMINIQUE ROMYR (US) 2012-07-19 — — US disclosed
US-20120184548-A1 CARBOXYLIC ACID ARYL AMIDES DOMINIQUE ROMYR (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184548-A1 CARBOXYLIC ACID ARYL AMIDES GOT1, PPARG, PPARA DYRK1A 2480/4885DYRK1B 3023/4885MAPT 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback